SEC Form 3 · accession 0000899243-18-028482
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Turtle
Officer — Chief Business Officer
Period of report
Nov 5, 2018
Accepted (ET)
Nov 7, 2018 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 107,305 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.00 | holding | — | — | — | — | Jun 21, 2028 | Common Stock | 23,920 | — | D |
| Stock Option (right to buy)F2 | $13.20 | holding | — | — | — | — | Nov 5, 2028 | Common Stock | 105,000 | — | D |
Explanation of responses
- F1The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 23,920 stock options (the "Grant") on June 22, 2018. The shares subject to the Grant shall vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- F2The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 105,000 stock options (the "Grant") on November 5, 2018. The shares subject to the Grant shall vest and become exercisable as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Remarks
Exhibit 24.1 - Power of Attorney